You already know your cholesterol number. But can you tell, right now, whether your body is aging faster than your birth certificate says — or slower? Lifespan is what medicine has always measured. Healthspan is what actually determines whether your last two decades are lived at full capacity or in slow decline. These are the tests that tell you which trajectory you’re on.
You’ve probably noticed it in people around you. Someone’s parent at sixty who moves like they’re eighty. A colleague at fifty who looks and performs like thirty-five. The difference isn’t luck, and it isn’t purely genetics. It’s a divergence between two numbers that medicine has spent decades conflating: how long a person lives, and how well.
Lifespan vs Healthspan — What the Numbers Actually Measure
Why ‘years lived’ is the wrong scoreboard
Think of your healthspan biomarkers like the dashboard of a long-haul vehicle. The odometer — your lifespan — tells you how many kilometres you’ve covered. But the dashboard, with its oil pressure gauge, engine temperature readout, battery charge indicator, and tyre wear sensor, tells you whether the vehicle will arrive in good condition or break down before the destination. Most people only check the odometer. This guide teaches you to read the full dashboard.
Harvard Medical School frames the core longevity question not as “how long will I live” but “how well will I live” — with measurable markers underpinning the answer. That reframe changes everything about what you should be testing, how often, and what counts as a result worth acting on. The odometer still matters. But it’s the least interesting instrument on the dashboard.
Defining the healthspan gap: the years between decline and death
Researchers who study aging now formally separate lifespan — total years lived — from healthspan — years lived free from serious disease and functional decline. The two are not the same metric and, critically, do not move together automatically. You can extend one without extending the other. In fact, that’s exactly what has happened at the population level.
Technological advancements have extended global life expectancy significantly over the past century, but healthspan has not kept pace — meaning more people are living longer in states of disease and dependency, not in additional years of vitality. The gap between the end of good health and the end of life — call it the healthspan gap — is where most of the suffering actually lives. Closing that gap is the real work of longevity medicine. And it starts with measuring the right things.
The Five Domains of Healthspan (And the Test for Each)
Domain 1 — Cardiovascular and Aerobic Capacity: VO2 Max
The single most powerful longevity biomarker most people have never had measured is VO2 max — the maximum volume of oxygen your body can use during intense exercise (the technical measure of cardiorespiratory fitness). It isn’t just a fitness metric. VO2 max testing is identified as potentially the best available test for heart health and longevity because it captures both cardiovascular fitness and metabolic efficiency in a single number. Low VO2 max is one of the strongest predictors of all-cause mortality across large populations — stronger, in fact, than most standard blood markers your GP routinely orders.
VO2 max is tested either through a formal incremental exercise test on a treadmill or bike with gas analysis, or estimated through submaximal protocols and wearable devices. The formal test is worth doing at least once to establish a true baseline. After that, a calibrated wearable can track trajectory. What you’re watching for isn’t the number in isolation — it’s whether it’s declining, stable, or improving relative to your age cohort.
Domain 2 — Metabolic Health: Fasting glucose, HbA1c, fasting insulin, triglycerides
Metabolic health is the domain where most people receive false reassurance. A fasting glucose in the “normal” range tells you remarkably little about what’s actually happening in your cells. The more informative marker is fasting insulin — a measure of how hard your pancreas is working to keep your blood sugar controlled. You can have perfectly normal fasting glucose while your insulin is chronically elevated, which is an early signal of insulin resistance — the gradual loss of your cells’ ability to respond to insulin’s signal — years before glucose numbers tip out of range.
Alongside fasting insulin, the metabolic dashboard includes HbA1c — a three-month average of blood sugar levels (glycated haemoglobin), and fasting triglycerides, which double as a proxy for how efficiently your body is processing dietary carbohydrates and fats. Together, these four markers give you a picture that no single test can. Most standard annual check-ups run one or two of them. You need all four, interpreted together, with an eye on trend rather than single-point snapshots.
Domain 3 — Musculoskeletal Integrity: Muscle mass, grip strength, DEXA scan
Muscle is not vanity. It is infrastructure. Muscle maintenance and metabolic function are identified as core pillars of healthspan optimisation — tracking muscle mass over time is a functional indicator of metabolic health, not merely an aesthetic one. Muscle tissue is metabolically active. It regulates glucose disposal, produces anti-inflammatory signalling molecules called myokines, and is the primary determinant of whether you remain physically independent in your seventies and eighties.
The gold standard measurement is a DEXA scan — dual-energy X-ray absorptiometry — which measures body composition by separating lean tissue, fat tissue, and bone mineral density with precision a standard scale cannot approach. When you request a DEXA, ask specifically for muscle mass and lean tissue distribution data, not just bone density. Grip strength, measured with a simple handheld dynamometer, is a low-tech but surprisingly powerful functional proxy — low grip strength in midlife is strongly associated with poor health outcomes in later decades. Both are worth tracking annually from your mid-forties onward.
Domain 4 — Inflammatory Status: hsCRP, IL-6
Chronic low-grade inflammation — a persistent, low-level activation of the immune system that produces no obvious symptoms but quietly accelerates tissue damage across every organ system — is one of the central mechanisms of accelerated aging. The technical term researchers use is inflammaging — the chronic, low-grade inflammatory state associated with biological aging. The two key measurable markers are hsCRP — high-sensitivity C-reactive protein — a liver-produced protein that rises in the blood when systemic inflammation is present, and IL-6 — interleukin-6 — a signalling molecule (cytokine) released by immune cells and fat tissue that drives the inflammatory cascade.
Standard CRP tests lack the sensitivity to detect the subtle elevations relevant to healthspan. Always request high-sensitivity CRP specifically. IL-6 is less routinely ordered but increasingly available through specialist panels. An hsCRP above 1.0 mg/L in the absence of acute illness is worth investigating — not as a diagnosis, but as a signal that something in your lifestyle, gut, sleep, or body composition is generating chronic inflammatory load.
Domain 5 — Biological Age Proxies: Epigenetic clocks and what they can and cannot tell you
Epigenetic clocks — algorithms that estimate biological age based on patterns of chemical tags on your DNA called methylation marks — represent the frontier of biological age testing. The most validated include the Horvath clock, GrimAge, and DunedinPACE, each measuring slightly different aspects of the aging process. What they offer is a number: your estimated biological age relative to your chronological age, and in some versions, your current pace of aging.
What they cannot yet offer is a precise, actionable prescription. Longevity science is actively developing a roadmap that distinguishes healthspan extension from lifespan extension as separate and not automatically linked clinical goals — and epigenetic testing is part of that frontier. The science is real. The commercial tests vary significantly in quality. If you pursue one, use a provider using validated algorithms, understand that test-retest variability exists, and treat the result as a directional signal rather than a verdict.
When to Test Each Biomarker — A Frequency Guide by Age Decade
Ages 35–45: Establish your baseline now, before the gradient starts
The most important thing you can do in your late thirties and early forties is establish numbers — not because something is wrong, but because you cannot track trajectory without a starting point. This is the decade where metabolic drift begins quietly, muscle mass starts its slow decline, and the first divergence between biological and chronological age becomes measurable. Run the full metabolic panel including fasting insulin, get a baseline DEXA, and if possible, get a formal VO2 max assessment. You are not looking for pathology. You are setting your personal reference range.
Ages 45–55: Shift from annual snapshots to trend tracking
By your mid-forties, a single data point is far less valuable than a trend line. This decade calls for consistent annual repetition of your core panel — metabolic markers, hsCRP, muscle mass — with enough frequency to see whether numbers are stable, drifting slowly, or shifting sharply. VO2 max should be reassessed every two years at minimum. Inflammatory markers warrant closer attention if your lifestyle, stress load, or body composition has changed. This is also the decade where the gap between “normal” and “optimal” begins to matter in practice.
Ages 55–60+: Frequency increases, focus shifts to rate of change
From your mid-fifties onward, the rate of change becomes the primary signal. A muscle mass that has declined two percent per year for three consecutive years is a different clinical picture than a stable baseline. Consider moving key metabolic markers to twice-yearly testing. DEXA frequency should increase. If you haven’t had a formal VO2 max assessment, this is the decade where the absolute value matters most directly for mortality risk stratification. The goal is not to discover problems — it is to catch rate of decline early enough that lifestyle intervention can reverse it.
How to Interpret Your Results Without Panicking (or Dismissing Them)
The difference between ‘normal’ and ‘optimal’ — why passing is not the goal
Population-level “normal” ranges were built by measuring large groups of people and defining the middle eighty or ninety percent as acceptable. The problem is that the population being measured is not healthy — it is average. An average that includes millions of people with undiagnosed insulin resistance, subclinical inflammation, and declining muscle mass will produce reference ranges that describe a trajectory toward disease, not away from it. Living longer without prioritising physical capacity and metabolic health is explicitly framed in longevity medicine as a failure of the lifespan-only model — and “normal” reference ranges are part of the same problem. Your target is optimal, not average.
Asian-specific reference ranges: why Singapore and Southeast Asian bodies need different benchmarks
For readers in Singapore and Southeast Asia, there is a specific and important calibration issue. Metabolic risk in Asian populations begins at lower BMI thresholds than Western norms — a BMI of 23 in a Southeast Asian adult carries similar cardiometabolic risk to a BMI of 25 to 27 in a European adult. This means standard Western metabolic panels, interpreted with Western reference ranges, will systematically underestimate risk in your body. Apply Asian-specific cutoffs for BMI, waist circumference, and triglycerides. If your doctor is using standard Western panels without adjustment, that is worth raising explicitly.
This is exactly the kind of question a routine annual check-up was not designed to answer — not because doctors don’t care, but because population-level reference ranges were never built to account for ethnicity-specific risk profiles, let alone your individual trajectory over time.
What rate of change tells you that a single data point never will
A single fasting insulin of 9 mIU/L is mildly elevated. That same number two years ago was 6 mIU/L. That is a different and more urgent story. The power of longitudinal testing is not in any individual result — it’s in the vector. Direction and speed of change are what separate early-stage drift from stable plateau. Build a simple personal health spreadsheet. Date every result. Track it. The trend line is the test.
What to Ask Your Doctor — A Conversation Starter Checklist
The tests your GP will order vs the tests you need to request
A standard annual check-up in Singapore or most of Southeast Asia will typically yield a lipid panel, fasting glucose, full blood count, and liver and kidney function markers. This is a reasonable acute care screen. It is not a healthspan protocol. The markers you will almost certainly need to request explicitly include fasting insulin, high-sensitivity CRP, IL-6, a DEXA scan with lean mass analysis, and a VO2 max assessment or referral. None of these are exotic. All are available. They simply fall outside the default order set of a ten-minute appointment.
- Fasting insulin (not just fasting glucose)
- HbA1c alongside the standard glucose
- High-sensitivity CRP (hsCRP — specify high-sensitivity)
- IL-6 if available through your provider’s lab panel
- DEXA scan with muscle mass and lean tissue data, not bone density alone
- VO2 max assessment or referral to a sports medicine physician or exercise physiologist
Red flags that warrant immediate investigation
Some results require more than trend-watching. An hsCRP above 3.0 mg/L in the absence of infection or injury warrants investigation of cause — not just monitoring. A VO2 max in the lowest age-matched quintile for your sex warrants a structured exercise programme and reassessment within three to six months. A fasting insulin above 12 mIU/L paired with normal fasting glucose should trigger a full metabolic workup including an oral glucose tolerance test. Rapidly declining grip strength or muscle mass on serial DEXA — defined as loss greater than one to two percent per year — warrants assessment for underlying causes including hormonal, nutritional, and activity-related factors.
How to build a testing protocol you can sustain over years, not just do once
Practical healthspan optimisation involves trackable health metrics — and real-world cases show measurable improvements in these markers through targeted lifestyle and testing protocols. The word “trackable” is the key. A test done once is a data point. A test repeated consistently over years is a story about your body’s trajectory. Build a protocol you will actually repeat: anchor it to the same time of year, the same fasting conditions, the same laboratory where possible. Consistency in method is what makes the numbers comparable. The goal is not a perfect result on day one — it is a clear-eyed picture of which direction you’re moving, and enough lead time to change course.
At your next GP or specialist visit, ask for three specific tests you likely have not had run together before: a VO2 max assessment (or referral for one), a fasting insulin level alongside your standard fasting glucose, and a DEXA scan for muscle mass rather than bone density alone. If any result sits in the “normal” range but below the optimal threshold for your age and sex, that is your first actionable data point — not a reason to panic, but a baseline to beat.
